RPA1 and systemic lupus erythematosus: ELISA may be helpful in identifyng additional anti-RPA-positive sera in theory; however, false positives via the reactivity of antibodies against DNA and proteins that interact with RPA seem to be quite common among patients with systemic rheumatic diseases, in particular in SLE and SjS (Figures 2b,e and 3b).